TABLE 1.
Hormonal parameters at baseline, on long‐acting testosterone replacement modalities (topical gels, intramuscular injection, and subcutaneous pellets), and on Natesto for men with hypogonadism (n = 27)
| Baseline | Long‐acting testosterone | Natesto | p value | |
|---|---|---|---|---|
| Testosterone (ng/dl) | 234.2 ± 53 | 761 ± 278 | 643.9 ± 170 | 0.0675 |
| Estradiol (pg/ml) | 23.7 ± 10 | 39.6 ± 19 | 21.5 ± 8 | 0.0001 |
| Follicle stimulating hormone (mIU/ml) | 4.5 ± 5 | 3.7 ± 4 | 0.519 | |
| Luteinizing hormone (mIU/ml) | 4.6 ± 4 | 4.6 ± 5 | 1.0 | |
| Semen volume (ml) | 2.6 ± 1 | |||
| Sperm concentration (mil/ml) | 50.7 ± 36 | |||
| Total motility (%) | 56.2 ± 18 | |||
| Forward progressive motility (%) | 28.6 ± 13 | |||
| Normal morphology (%) | 4.9 ± 4 | |||
| Total motile sperm count (mil) | 69.1 ± 65 |
Note: Semen parameters on Natesto. Results are expressed as means ± standard deviations. p values for testosterone and estradiol levels are comparing men on long‐acting forms of testosterone replacement versus Natesto. p values for follicle stimulating hormone and luteinizing hormone levels are comparing baseline levels prior to any treatment to treatment with Natesto. Bold value indicates statistical significance.